Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:25 PM
Ignite Modification Date:
2025-12-24 @ 11:25 PM
NCT ID:
NCT01952756
Eligibility Criteria:
Inclusion Criteria:
* ankle-brachial index (ABI) less than 0.9 in one or both legs but no obvious symptoms of intermittent claudication
Exclusion Criteria:
* obvious symptoms of intermittent claudication
* severe PAD (Fontaine grading \> 3) or critical limb ischemia in at least one leg
* severe liver dysfunction (transaminases \>10 times of upper normal limit, history of liver cirrhosis, or hepatoma)
* \> stage 4 chronic kidney disease (end-stage renal disease with chronic dialysis not excluded)
* left ventricular ejection fraction \<50% by echocardiography
* documented active malignancy
* chronic inflammatory disease
* planned coronary intervention or endovascular therapy or bypass surgery within 3 months
* known drug allergy history for cilostazol
* current use of cilostazol or any other cAMP-elevator
* premenopausal women
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
20 Years
Study:
NCT01952756
Study Brief:
Protocol Section:
NCT01952756